8-K: Clarivate Raises 2025 Revenue Outlook on Q3 Performance

Clarivate Plc reported improved Q3 2025 net loss and raised its full-year revenue guidance, driven by organic ACV growth and strategic initiatives.

Summary

• Total revenues for Q3 2025 were $623.1 million, a slight increase from $622.2 million in Q3 2024.
• Organic revenues for Q3 2025 decreased by 0.1%, as organic subscription growth of 1.2% was offset by lower organic re-occurring and transactional revenues.
• Organic Annualized Contract Value (ACV) grew 1.6% compared to September 30, 2024, and the mix of organic recurring revenue to total revenue improved to 88% through nine months of 2025, up from 80% in FY 2024.
• Net loss significantly improved to $28.3 million in Q3 2025 from $65.6 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $252.4 million, a 4.5% decrease from $264.4 million in Q3 2024.
• Through nine months of 2025, total revenues were $1,838.2 million, a 2.9% decrease from $1,893.7 million in the prior year, primarily due to inorganic divestitures and disposals.
• Net cash provided by operating activities through nine months of 2025 was $468.6 million, and free cash flow was $276.1 million.
• The company repurchased 11.7 million ordinary shares for approximately $50 million in Q3 2025, contributing to a total of 34.8 million shares repurchased for $150 million through nine months of 2025.
• Clarivate repaid $100 million of debt in September 2025, reducing total debt outstanding to $4,470.2 million as of September 30, 2025.
• The full-year 2025 revenue outlook was raised to a range of $2.42 billion to $2.45 billion, up from the prior guidance of $2.28 billion to $2.40 billion.
• The company's Value Creation Plan is driving accelerated product and AI development, improved sales execution, and a focus on increasing core subscription and recurring revenue mix.

Sentiment

Score: 7

Explanation: The company reported improved net loss and raised its full-year revenue outlook, indicating positive momentum. Strategic initiatives like the Value Creation Plan, AI investments, and debt repayment are favorable. However, adjusted earnings and EBITDA saw slight declines, and organic revenue growth was nearly flat, suggesting ongoing challenges in some areas despite overall improvements and a positive outlook revision.

Positives

• Net loss significantly improved in Q3 2025 to $28.3 million from $65.6 million in Q3 2024.
• Full-year 2025 revenue outlook was raised to $2.42 billion $2.45 billion, reflecting increased transactional book sales and favorable foreign exchange impact.
• Organic ACV grew 1.6% compared to September 30, 2024, and increased 30 basis points sequentially in Q3 2025.
• The mix of organic recurring revenue to total revenue improved by 800 basis points to 88% through nine months of 2025 compared to 80% for the prior year.
• Organic subscription revenue growth was 1.2% in Q3 2025.
• The company repurchased 11.7 million ordinary shares for approximately $50 million in Q3 2025, demonstrating commitment to shareholder returns.
• $100 million of debt was repaid in September 2025, reducing total debt outstanding.
• Academia & Government segment showed solid 2% organic ACV and subscription revenue growth, securing over 100 new contracts YTD and a multi-million dollar Web of Science renewal.
• Life Sciences & Healthcare segment's organic ACV accelerated to 2% growth, with new AI-powered regulatory assistant launched.
• The Value Creation Plan is on track, driving product innovation, AI development, and operational efficiencies.
• Free Cash Flow CAGR of 4% from 2022-2025F and an average FCF Conversion of 35% over the same period.

Negatives

• Organic revenues for Q3 2025 decreased by 0.1%, as organic subscription growth was offset by lower organic re-occurring and transactional revenues.
• Adjusted net income decreased by 11.0% to $119.3 million in Q3 2025 from $134.1 million in Q3 2024.
• Adjusted diluted EPS decreased to $0.18 in Q3 2025 from $0.19 in Q3 2024.
• Adjusted EBITDA decreased by 4.5% to $252.4 million in Q3 2025 from $264.4 million in Q3 2024.
• Net cash provided by operating activities through nine months of 2025 decreased by 7.3% to $468.6 million from $505.3 million in the prior year period.
• Free cash flow through nine months of 2025 decreased by 7.5% to $276.1 million from $298.4 million in the prior year period.
• Total revenues through nine months of 2025 decreased by 2.9% due to inorganic divestitures and disposals.
• Organic re-occurring revenues decreased 3.2% in Q3 2025, primarily due to lower IP volumes and sales.
• Organic transactional revenues decreased 2.8% in Q3 2025.
• Total ACV declined 3.4% to $1,542.7 million as of September 30, 2025, compared to $1,596.4 million as of September 30, 2024, primarily due to the ScholarOne divestiture and wind-down of certain product groups.

Risks

• Forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different.
• The company refers to risk factors described in Item 1A. Risk Factors in its annual report on Form 10-K, along with other filings with the U.S. Securities and Exchange Commission (SEC).
• Future results may be affected by items adjusted in non-GAAP measures, or projections and estimates may not be realized in their entirety or at all.

Future Outlook

Clarivate raised its full-year 2025 revenue outlook to a range of $2.42 billion to $2.45 billion, reflecting increased transactional book sales prior to a planned June 2026 disposal and the favorable impact of a weaker U.S. dollar. The company reaffirmed its guidance for Organic ACV growth of 1.0% to 2.0%, Recurring Organic Revenue Growth of (1.0)% to 1.0%, Adjusted EBITDA of $940 million to $1.00 billion, Adjusted EBITDA Margin of 40.5% to 42.5%, Adjusted Diluted EPS of $0.60 to $0.70, and Free Cash Flow of $300 million to $380 million. Management expects continued growth acceleration in organic ACV and anticipates recurring organic growth in the upper half of its range. The company plans to complete its review of strategic alternatives and disclose findings at year-end earnings in February.

Management Comments

• "The third quarter demonstrated continued improved financial and operational performance, underscoring the effectiveness of our Value Creation Plan and the increased focus, growth and innovation it enables." Matti Shem Tov, CEO
• "By accelerating product and AI development, investing in proprietary assets, and collaborating closely with our customers, we are optimizing our business model and supporting improved sales execution, which is driving organic ACV growth." Matti Shem Tov, CEO
• "We remain committed to increasing our core subscription and recurring revenue mix, rationalizing our solutions portfolio, and unlocking greater value for our shareholders." Matti Shem Tov, CEO
• "With strong talent, disciplined cost management, and enterprise technology as key enablers, we are well-positioned to deliver sustainable growth and long-term success." Matti Shem Tov, CEO
• "The full year 2025 revenue outlook was revised upward, reflecting increased transactional book sales prior to the planned June 2026 disposal, as well as the favorable impact of a weaker U.S. dollar." Jonathan Collins, Executive Vice President and Chief Financial Officer
• "During the quarter, as part of our commitment to shareholder returns and disciplined capital management, we allocated $50 million of cash flow towards the repurchase of approximately 12 million shares and called $100 million of our 2026 bonds." Jonathan Collins, Executive Vice President and Chief Financial Officer
• "We remain focused on our strategic priorities—investing in innovation, driving operational efficiencies, and maximizing long-term value for our shareholders." Jonathan Collins, Executive Vice President and Chief Financial Officer

Industry Context

Clarivate operates in the information services industry, providing data, insights, and workflow solutions across Academia & Government, Intellectual Property, and Life Sciences & Healthcare. The company's focus on accelerating AI development and transitioning to a subscription-based model aligns with broader industry trends towards digital transformation, data-driven decision-making, and recurring revenue models. The reported organic ACV growth and improved recurring revenue mix suggest successful adaptation to these trends, while the continued investment in AI-powered solutions positions Clarivate to enhance its competitive edge in specialized information markets.

Stakeholder Impact

• Shareholders: Positive impact from share repurchases ($150 million YTD, $50 million in Q3) and debt repayment ($100 million in Q3), indicating commitment to shareholder returns and financial health. Raised revenue outlook and ongoing Value Creation Plan aim to unlock greater long-term value.
• Customers: Benefits from accelerated product and AI development, new AI-powered solutions (e.g., Derwent Patent Monitor AI Threat Rating, Cortellis Regulatory Assistant), and improved sales execution, leading to enhanced workflow solutions and insights.
• Employees: The Value Creation Plan emphasizes "strong talent" and "disciplined cost management," implying a focus on efficiency which could lead to restructuring, but also investment in AI and innovation could create new opportunities. Restructuring costs are mentioned in non-GAAP adjustments.
• Creditors: Positive impact from $100 million accelerated debt repayment and extension of interest rate swaps, demonstrating disciplined capital management and efforts to manage debt obligations. Net leverage remains at 4x.

Next Steps

• Continue rapid deployment of Agentic AI and release new AI-native solutions.
• Extend AI-powered capabilities across the flagship product portfolio.
• Accelerate organic ACV and recurring revenue growth through focused sales execution.
• Deepen customer engagement to drive sustainable account growth.
• Enhance sales productivity through AI-powered insights and enablement.
• Utilize Agentic AI to drive operational efficiency and margin expansion.
• Embed organization-wide AI adoption to drive operational excellence and cost efficiencies.
• Complete exit from Academia & Government transactional book sales.
• Exit Life Sciences & Healthcare Real-World Data reselling market.
• Complete comprehensive review and assessment of strategic alternatives and disclose at year-end earnings in February.
• Flexibility in deployment of $100 million in Q4 for capital allocation.

Key Dates

Recommendation

Clarivate's Q3 2025 results show a mixed performance with improved net loss and a raised revenue outlook, which are positive signals. However, adjusted earnings and EBITDA declined, and organic revenue growth was nearly flat. The company's strategic focus on AI innovation, subscription growth, and disciplined capital allocation (share repurchases, debt repayment) is commendable and could drive long-term value. The upcoming disclosure of strategic alternatives in February could be a significant catalyst. Given the current mixed financial metrics but clear strategic direction and commitment to shareholder value, a 'hold' recommendation is appropriate for investors awaiting further clarity on the Value Creation Plan's full impact and the outcome of the strategic alternatives review.

Keywords

Clarivate, CLVT, Earnings, Q3 2025, Financial Results, SEC Filing, 8-K, Revenue Outlook, Adjusted EBITDA, Organic ACV, Free Cash Flow, Share Repurchase, Debt Repayment, Value Creation Plan, Subscription Revenue, Academia & Government, Intellectual Property, Life Sciences & Healthcare, AI Innovation